Merck & Co has contributed to Themis’ series D round after signing a strategic partnership agreement last month to develop vaccines for undisclosed diseases.

Moti has received funding from SIG Asia to close its series A round following a $31m first tranche in July.

Boundless Bio, which is developing treatments focusing on extrachromosomal DNA, has raised $46.4m from investors including Alexandria Venture Investments.

The Lundbeck and Upsher-Smith-backed drug development technology provider reportedly raised the funding at half the $2bn valuation of its last round in 2018.

High school esports platform developer PlayVS, which counts Adidas, Samsung Next and WndrCo as investors, secured series C cash to take its total funding to $96m.

Edgewise Therapeutics completed a $50m round co-led by Novo that will advance product candidates addressing Duchenne and Becker muscular dystrophy.

The diabetes management app developer raised $40m in a round led by Bayer, which has also signed a licensing agreement with the company.

Edenred, Samsung, Swiss Post and Swisscom all returned in a $45m series B round for Beekeeper, which is targeting accelerated adoption of its workforce communications platform.

The children's debit card provider has now raised more than $77m in total, having secured new funding from investors including JPMorgan Chase, Wells Fargo and Live Oak Bank.

Citi Ventures, Santander InnoVentures and American Express Ventures chipped in for a $52.8m series C round revealed together with approximately $7.6m in follow-on funding.